Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

Swiss biopharma Roche is betting more than $1 billion that Sarepta Therapeutics, which recently won FDA approval for its second RNA medicine for Duchenne muscular dystrophy, will get its lead gene therapy treatment across the finish line too.